Pliant Therapeutics (PLRX) Competitors $1.52 +0.02 (+1.33%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$1.52 -0.01 (-0.33%) As of 10/3/2025 06:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock PLRX vs. DRUG, ANNX, LXEO, BNTC, DMAC, ALT, CGEM, RCKT, LBRX, and TVRDShould you be buying Pliant Therapeutics stock or one of its competitors? The main competitors of Pliant Therapeutics include Bright Minds Biosciences (DRUG), Annexon (ANNX), Lexeo Therapeutics (LXEO), Benitec Biopharma (BNTC), DiaMedica Therapeutics (DMAC), Altimmune (ALT), Cullinan Therapeutics (CGEM), Rocket Pharmaceuticals (RCKT), LB Pharmaceuticals (LBRX), and Tvardi Therapeutics (TVRD). These companies are all part of the "pharmaceutical products" industry. Pliant Therapeutics vs. Its Competitors Bright Minds Biosciences Annexon Lexeo Therapeutics Benitec Biopharma DiaMedica Therapeutics Altimmune Cullinan Therapeutics Rocket Pharmaceuticals LB Pharmaceuticals Tvardi Therapeutics Bright Minds Biosciences (NASDAQ:DRUG) and Pliant Therapeutics (NASDAQ:PLRX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, risk, dividends, media sentiment and institutional ownership. Do analysts rate DRUG or PLRX? Bright Minds Biosciences presently has a consensus price target of $81.00, suggesting a potential upside of 52.08%. Pliant Therapeutics has a consensus price target of $8.19, suggesting a potential upside of 438.65%. Given Pliant Therapeutics' higher possible upside, analysts plainly believe Pliant Therapeutics is more favorable than Bright Minds Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bright Minds Biosciences 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11Pliant Therapeutics 1 Sell rating(s) 12 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Do institutionals & insiders hold more shares of DRUG or PLRX? 40.5% of Bright Minds Biosciences shares are held by institutional investors. Comparatively, 97.3% of Pliant Therapeutics shares are held by institutional investors. 42.7% of Bright Minds Biosciences shares are held by company insiders. Comparatively, 6.4% of Pliant Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Does the media refer more to DRUG or PLRX? In the previous week, Bright Minds Biosciences had 3 more articles in the media than Pliant Therapeutics. MarketBeat recorded 3 mentions for Bright Minds Biosciences and 0 mentions for Pliant Therapeutics. Bright Minds Biosciences' average media sentiment score of 0.92 beat Pliant Therapeutics' score of 0.00 indicating that Bright Minds Biosciences is being referred to more favorably in the media. Company Overall Sentiment Bright Minds Biosciences Positive Pliant Therapeutics Neutral Is DRUG or PLRX more profitable? Bright Minds Biosciences' return on equity of -20.96% beat Pliant Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Bright Minds BiosciencesN/A -20.96% -20.66% Pliant Therapeutics N/A -73.45%-55.66% Which has stronger valuation & earnings, DRUG or PLRX? Bright Minds Biosciences has higher earnings, but lower revenue than Pliant Therapeutics. Bright Minds Biosciences is trading at a lower price-to-earnings ratio than Pliant Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBright Minds BiosciencesN/AN/A-$2.06M-$0.93-57.27Pliant Therapeutics$1.58M59.06-$210.30M-$3.40-0.45 Which has more risk & volatility, DRUG or PLRX? Bright Minds Biosciences has a beta of -6.17, suggesting that its stock price is 717% less volatile than the S&P 500. Comparatively, Pliant Therapeutics has a beta of 1.4, suggesting that its stock price is 40% more volatile than the S&P 500. SummaryBright Minds Biosciences beats Pliant Therapeutics on 10 of the 15 factors compared between the two stocks. Get Pliant Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PLRX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PLRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PLRX vs. The Competition Export to ExcelMetricPliant TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$93.31M$3.36B$6.13B$10.58BDividend YieldN/A2.28%5.66%4.69%P/E Ratio-0.4522.1486.8826.70Price / Sales59.06452.31605.42240.56Price / CashN/A46.3226.3031.09Price / Book0.309.9012.536.57Net Income-$210.30M-$52.45M$3.30B$276.78M7 Day PerformanceN/A5.22%4.28%2.42%1 Month Performance-18.28%10.61%6.90%8.63%1 Year Performance-86.82%25.03%70.54%31.60% Pliant Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PLRXPliant Therapeutics3.8101 of 5 stars$1.52+1.3%$8.19+438.7%-86.8%$93.31M$1.58M-0.4590DRUGBright Minds Biosciences2.9326 of 5 stars$57.45+9.0%$81.00+41.0%+4,491.4%$371.36MN/A-61.77N/ANews CoverageAnalyst DowngradeANNXAnnexon3.0335 of 5 stars$3.12-7.4%$12.50+300.6%-49.3%$370.32MN/A-2.4260News CoveragePositive NewsGap UpHigh Trading VolumeLXEOLexeo Therapeutics2.1582 of 5 stars$6.66-1.6%$15.33+130.2%-23.6%$365.59M$650K-2.0458Positive NewsBNTCBenitec Biopharma1.995 of 5 stars$13.99+2.1%$24.80+77.3%+46.1%$359.63M$80K-9.5220DMACDiaMedica Therapeutics2.5172 of 5 stars$6.91-0.4%$12.33+78.5%+62.2%$358.72MN/A-10.0120News CoverageAnalyst UpgradeALTAltimmune3.236 of 5 stars$3.79-5.3%$17.40+359.1%-37.2%$353.03M$20K-3.2150CGEMCullinan Therapeutics2.1565 of 5 stars$5.97+0.2%$26.00+335.5%-63.9%$352.08MN/A-1.8530RCKTRocket Pharmaceuticals4.7733 of 5 stars$3.28+0.6%$16.73+410.2%-80.8%$351.77MN/A-1.31240News CoverageAnalyst ForecastLBRXLB PharmaceuticalsN/A$15.24-1.3%N/AN/A$346.52MN/A0.0016Gap DownTVRDTvardi Therapeutics3.2965 of 5 stars$36.90+1.6%$64.25+74.1%N/A$340.59M$7.14M0.0080News CoverageGap Up Related Companies and Tools Related Companies DRUG Alternatives ANNX Alternatives LXEO Alternatives BNTC Alternatives DMAC Alternatives ALT Alternatives CGEM Alternatives RCKT Alternatives LBRX Alternatives TVRD Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PLRX) was last updated on 10/5/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredU.S. Government Sparking Crypto RallyU.S. Puts GDP on the Blockchain Could this spark the next crypto supercycle? Discover the altcoins poised t...Crypto 101 Media | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredRIP USA"The America you knew is dying in front of you" That's the urgent warning the former $200 million hedge fun...Stansberry Research | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pliant Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pliant Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
